|
Neuroendocrine Tumors
|
0.380 |
Biomarker
|
group |
BEFREE |
Performance of DAXX Immunohistochemistry as a Screen for DAXX Mutations in Pancreatic Neuroendocrine Tumors.
|
30747827 |
2019 |
|
Neuroendocrine Tumors
|
0.380 |
GeneticVariation
|
group |
BEFREE |
DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors.
|
31819132 |
2019 |
|
Neuroendocrine Tumors
|
0.380 |
GeneticVariation
|
group |
BEFREE |
DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.
|
30342802 |
2018 |
|
Neuroendocrine Tumors
|
0.380 |
Biomarker
|
group |
BEFREE |
Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
|
28371511 |
2017 |
|
Neuroendocrine Tumors
|
0.380 |
Biomarker
|
group |
BEFREE |
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
|
28591701 |
2017 |
|
Neuroendocrine Tumors
|
0.380 |
Biomarker
|
group |
BEFREE |
A lack of ATRX or DAXX in a sellar NET suggests a nonpituitary NET, probably of pancreatic origin.
|
28719461 |
2017 |
|
Neuroendocrine Tumors
|
0.380 |
Biomarker
|
group |
BEFREE |
In this study, we analyzed the expression of the candidate genes mammalian target of rapamycin (mTOR), alpha thalassemia/mental retardation syndrome X-linked (ATRX), and death domain-associated protein (DAXX) to investigate the specific oncogenetics and potential therapeutic options for ileal NETs.
|
25439321 |
2015 |
|
Neuroendocrine Tumors
|
0.380 |
Biomarker
|
group |
BEFREE |
These results support the hypothesis that DAXX- and ATRX-negative tumors are a more aggressive subtype of pNET, and could lead to identification of strategies to target CIN in pancreatic tumors.
|
24148618 |
2014 |
|
Neuroendocrine Tumors
|
0.380 |
Biomarker
|
group |
CTD_human |
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
|
21252315 |
2011 |
|
Glioblastoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3.
|
29799523 |
2018 |
|
Glioblastoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Moreover, DAXX expression anti-correlates with PTEN expression in GBM patient samples.
|
28497778 |
2017 |
|
Glioblastoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Pediatric GBMs have a distinctive molecular pathogenesis, as H3F3A and DAXX mutations are frequent, and their gene expression profile is different than adult GBMs.
|
24445767 |
2015 |
|
Glioblastoma
|
0.330 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of pancreas
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Finally, interrogation of the Oncomine(TM) database suggests that DAXX overexpression is associated with malignant transformation in several human cancers, including prostate and pancreatic cancers.
|
25903140 |
2015 |
|
Pancreatic Neoplasm
|
0.310 |
Biomarker
|
disease |
BEFREE |
These results support the hypothesis that DAXX- and ATRX-negative tumors are a more aggressive subtype of pNET, and could lead to identification of strategies to target CIN in pancreatic tumors.
|
24148618 |
2014 |
|
Pancreatic Neoplasm
|
0.310 |
Biomarker
|
disease |
CTD_human |
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
|
21252315 |
2011 |
|
Malignant neoplasm of pancreas
|
0.310 |
Biomarker
|
disease |
CTD_human |
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
|
21252315 |
2011 |
|
Adrenocortical carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Integrated genomic characterization of adrenocortical carcinoma.
|
24747642 |
2014 |
|
Pancreatic Endocrine Carcinoma
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Hypoxia-Ischemia, Brain
|
0.200 |
Biomarker
|
disease |
RGD |
Blocking Daxx trafficking attenuates neuronal cell death following ischemia/reperfusion in rat hippocampus CA1 region.
|
21843499 |
2011 |
|
Transient Ischemic Attack
|
0.200 |
Therapeutic
|
disease |
RGD |
Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats.
|
17967739 |
2007 |
|
Rheumatoid Arthritis
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis.
|
21156761 |
2011 |
|
Rheumatoid Arthritis
|
0.110 |
AlteredExpression
|
disease |
BEFREE |
Our findings indicate that in RA SFs overexpression of SENP1 can alter the SUMO-1-mediated recruitment of DAXX to PML NBs, thus influencing the proapoptotic effects of DAXX.
|
17360386 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
|
31029033 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found that the cumulative number of mutations detected in panNETs >2 cm was significantly higher (p = 0.03) relative to smaller tumors, while mutations of DAXX were significantly more frequent in the cohort of larger tumors (p = 0.05).
|
31819132 |
2019 |